Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.17% | -62.65% | -112.64% | 45.98% | -82.98% |
| Total Depreciation and Amortization | 2.20% | -7.14% | 180.00% | -69.83% | -0.85% |
| Total Amortization of Deferred Charges | 1.79% | -4.27% | -11.36% | -- | -- |
| Total Other Non-Cash Items | -56.15% | 67.91% | -28.02% | -1.96% | 1,170.63% |
| Change in Net Operating Assets | -41.68% | 233.78% | 68.97% | 16.18% | -243.83% |
| Cash from Operations | -3.45% | -1.73% | -5,889.66% | 98.24% | -108.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 109.97% | -4,770.22% | 47.65% | 2.30% | 38.41% |
| Cash from Investing | 109.97% | -4,770.22% | 47.65% | 2.30% | 38.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 3,644.47% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 3,428.48% | 263.49% | -103.54% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -306.42% | 129.10% | -187.63% | -116.70% | 346.10% |